艾塞那肽替代胰岛素治疗2型糖尿病患者的临床分析

被引:21
作者
刘敏
荆丹清
白桦
尹士男
机构
[1] 解放军总医院第一附属医院内分泌科
关键词
艾塞那肽; 胰岛素; 2型糖尿病; 自我血糖监测; 血糖波动;
D O I
暂无
中图分类号
R587.1 [糖尿病];
学科分类号
100201 [内科学];
摘要
目的总结应用艾塞那肽成功替代胰岛素治疗的2型糖尿病患者的临床特点,并比较胰岛素和艾塞那肽的降糖效果以及对血糖稳定性的影响。方法回顾分析了成功应用艾塞那肽替代胰岛素治疗的21例2型糖尿病患者的临床资料和自我血糖监测记录,应用配对t检验对患者先后应用胰岛素和艾塞那肽治疗期间的血糖值进行比较分析。结果患者多为中青年,糖尿病病程短,体型肥胖,平均糖化血红蛋白为(9.9±3.0)%,空腹C肽为(0.43±0.13)pmol/ml,餐后2 h C肽为(1.08±0.66)pmol/ml。应用艾塞那肽期间,患者血糖水平和达标率明显优于胰岛素治疗期间的血糖(P<0.01),同时全天血糖标准差、最大血糖波动幅度、四分位血糖波动范围、餐后血糖波动幅度、空腹血糖变异系数和日间血糖平均绝对差均明显低于胰岛素治疗期间的血糖波动情况(P<0.05)。回归分析结果显示血糖波动性指标主要与餐后血糖呈正相关,与空腹血糖无关。结论胰岛功能轻度受损的肥胖2型糖尿病患者应用艾塞那肽不仅可以良好地控制血糖,而且能够减少血糖的波动性。
引用
收藏
页码:47 / 51
页数:5
相关论文
共 7 条
[1]
自我血糖监测对预测糖调节异常者与糖尿病患者的日内血糖波动的价值.[J].吕丽芳;王椿;刘关键;陈大伟;陈利鸿;李永恒;周健;贾伟平;冉兴无;.四川大学学报(医学版).2011, 01
[2]
Exenatide Added to Insulin Therapy: A Retrospective Review of Clinical Practice Over Two Years in an Academic Endocrinology Outpatient Setting [J].
Yoon, Nancy M. ;
Cavaghan, Melissa K. ;
Brunelle, Rocco L. ;
Roach, Paris .
CLINICAL THERAPEUTICS, 2009, 31 (07) :1511-1523
[3]
One-Year Treatment With Exenatide Improves ß-Cell Function; Compared With Insulin Glargine; in Metformin-Treated Type 2 Diabetic Patients: A randomized; controlled trial.[J].Bunck; Mathijs C;Diamant; Michaela;Cornér; Anja;Eliasson; Bjorn;Malloy; Jaret L;Shaginian; Rimma M;Deng; Wei;Kendall; David M;Taskinen; Marja-Riitta;Smith; Ulf;Yki-Järvinen; Hannele;Heine; Robert J.Diabetes Care.2009, 5
[4]
CNS GLP-1 regulation of peripheral glucose homeostasis [J].
Sandoval, Darleen .
PHYSIOLOGY & BEHAVIOR, 2008, 94 (05) :670-674
[5]
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial [J].
Barnett, Anthony H. ;
Burger, Jude ;
Johns, Don ;
Brodows, Robert ;
Kendall, David M. ;
Roberts, Anthony ;
Trautmann, Michael E. .
CLINICAL THERAPEUTICS, 2007, 29 (11) :2333-2348
[6]
A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study [J].
Nauck, M. A. ;
Duran, S. ;
Kim, D. ;
Johns, D. ;
Northrup, J. ;
Festa, A. ;
Brodows, R. ;
Trautmann, M. .
DIABETOLOGIA, 2007, 50 (02) :259-267
[7]
Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes [J].
Blonde, L. ;
Klein, E. J. ;
Han, J. ;
Zhang, B. ;
Mac, S. M. ;
Poon, T. H. ;
Taylor, K. L. ;
Trautmann, M. E. ;
Kim, D. D. ;
Kendall, D. M. .
DIABETES OBESITY & METABOLISM, 2006, 8 (04) :436-447